Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control

被引:19
作者
Bloch, Evan M. [1 ]
West, Sheila K. [2 ,7 ]
Mabula, Kasubi [3 ]
Weaver, Jerusha [2 ,7 ]
Mrango, Zakayo [4 ]
Munoz, Beatriz [2 ,7 ]
Lietman, Thomas [5 ,8 ]
Coles, Christian [6 ,9 ]
机构
[1] Johns Hopkins Sch Med, Dept Pathol, 600 North Wolfe St Carnegie, Baltimore, MD 21287 USA
[2] Johns Hopkins Sch Med, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA
[3] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol, Dar Es Salaam, Tanzania
[4] Natl Inst Med Res, Kilosa, Tanzania
[5] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA
[6] Uniformed Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD USA
[7] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21205 USA
[8] Univ Calif San Francisco, Proctor Fdn, San Francisco, CA 94143 USA
[9] Uniformed Serv Univ Hlth Sci, Preventat Med & Biostat, Bethesda, MD 20814 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
STREPTOCOCCUS-PNEUMONIAE; CARRIAGE; IMPACT; RISK;
D O I
10.4269/ajtmh.17-0022
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Mass administration of azithromycin (MDA) is integral to trachoma control. Recent studies suggest that MDA may increase drug-resistant pathogens, yet findings from prior studies suggest little long-term impact on resistance. This disparity may be linked to differences in pre-MDA community-level resistance patterns. We describe carriage prevalence and antibiotic resistance patterns for Streptococcus pneumoniae (Spn) (nasopharyngeal swab collection), Staphylococcus aureus (SA) (nasopharyngeal swabs), and Escherichia coli (EC) (rectal swabs) in 1,047 children ages 1-59 months in a district with MDA cessation 4 years ago. Antibiotic susceptibility was evaluated by disk diffusion and Etest. The carriage rates for Spn, SA, and EC were 43.5% (455/1,047), 13.2% (138/1,047), and 61.7% (646/1,047), respectively. Resistance to AZM was observed in 14.3%, 29.0%, and 16.6% of the Spn, SA, and EC isolates, respectively. Spn resistance was variable (0-67%) by hamlet. Future analyses will assess the influence of pre-MDA antibiotic resistance patterns on those observed following MDA.
引用
收藏
页码:815 / 818
页数:4
相关论文
共 11 条
[1]  
[Anonymous], 2014, Clsi. M100-S24
[2]   Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae [J].
Batt, SL ;
Charalambous, BM ;
Solomon, AW ;
Knirsch, C ;
Massae, PA ;
Safari, S ;
Sam, NE ;
Everett, D ;
Mabey, DCW ;
Gillespie, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2765-2769
[3]   Mass Distribution of Azithromycin for Trachoma Control Is Associated With Increased Risk of Azithromycin-Resistant Streptococcus pneumoniae Carriage in Young Children 6 Months After Treatment [J].
Coles, Christian L. ;
Mabula, Kasubi ;
Seidman, Jessica C. ;
Levens, Joshua ;
Mkocha, Harran ;
Munoz, Beatriz ;
Mfinanga, Sayoki G. ;
West, Sheila .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) :1519-1526
[4]   Mass Distribution of Azithromycin for Trachoma Control Is Associated With Short-term Reduction in Risk of Acute Lower Respiratory Infection in Young Children [J].
Coles, Christian L. ;
Levens, Joshua ;
Seidman, Jessica C. ;
Mkocha, Harran ;
Munoz, Beatriz ;
West, Sheila .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (04) :341-346
[5]   Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal [J].
Fry, AM ;
Jha, HC ;
Lietman, TM ;
Chaudhary, JSP ;
Bhatta, RC ;
Elliott, J ;
Hyde, T ;
Schuchat, A ;
Gaynor, B ;
Dowell, SF .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :395-402
[6]   Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease [J].
Gray, GC ;
McPhate, DC ;
Leinonen, M ;
Cassell, GH ;
Deperalta, EP ;
Putnam, SD ;
Karcher, JA ;
Sawyer, MH ;
Laurila, A ;
Connor, JD .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :103-110
[7]   The Decline of Pneumococcal Resistance after Cessation of Mass Antibiotic Distributions for Trachoma [J].
Haug, Sara ;
Lakew, Takele ;
Habtemariam, Gabremaskal ;
Alemayehu, Wondu ;
Cevallos, Vicky ;
Zhou, Zhaoxia ;
House, Jenafir ;
Ray, Kathryn ;
Porco, Travis ;
Rutar, Tina ;
Keenan, Jeremy ;
Lietman, Thomas M. ;
Gaynor, Bruce D. .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) :571-574
[8]   European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria [J].
Kahlmeter, G ;
Brown, DFJ ;
Goldstein, FW ;
MacGowan, AP ;
Mouton, JW ;
Österlund, A ;
Rodloff, A ;
Steinbakk, M ;
Urbaskova, P ;
Vatopoulos, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :145-148
[9]   A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae [J].
Leach, AJ ;
ShelbyJames, TM ;
Mayo, M ;
Gratten, M ;
Laming, AC ;
Currie, BJ ;
Mathews, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) :356-362
[10]   Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control [J].
Seidman, Jessica C. ;
Coles, Christian L. ;
Silbergeld, Ellen K. ;
Levens, Joshua ;
Mkocha, Harran ;
Johnson, Lashaunda B. ;
Munoz, Beatriz ;
West, Sheila K. .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2014, 43 (04) :1105-1113